Physician profile
David Castrilli
NPI 1033477666
$1,368.24
in general payments reported to CMS, 2019-2025
20 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $54.05 · 2023: $55.86 · 2024: $455 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $286.89 | 2019-2025 | Rybelsus, Ozempic |
| Silk Road Medical, INC. | $136.77 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Amgen INC. | $112.00 | 2023-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $92.77 | 2019-2025 | |
| Abbvie INC. | $82.30 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.95 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $73.39 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $67.96 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.67 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $60.75 | 2019 | |
| Glaxosmithkline, LLC. | $54.80 | 2019-2020 | |
| Abbott Laboratories | $46.03 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $42.47 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $41.97 | 2024 | |
| Inspire Medical Systems, INC. | $29.51 | 2025 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.75 | 2019 | |
| Resmed Corp | $22.71 | 2025 | |
| Lundbeck LLC | $19.87 | 2024 | Rexulti |
| Genentech USA, INC. | $16.60 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.08 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Castrilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.